Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

BACKGROUND: The FLAURA study was a multicenter, double-blind, Phase 3 study in which patients with previously untreated epidermal growth factor receptor mutation-positive advanced non-small-cell lung carcinoma were randomized 1:1 to oral osimertinib 80 mg once daily or standard-of-care (gefitinib 25...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Jpn J Clin Oncol
Hlavní autoři: Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6322567/
https://ncbi.nlm.nih.gov/pubmed/30508196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyy179
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky